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INTRODUCTION:Medulloblastoma (MB) is the most commonmalignant
brain tumor in children. Four different molecular subgroups are recognized,
which differ in gene expression, genomic aberrations, histology, demographics
and survival: WNT and SHH groups, having specific mutations in the homon-
ymous pathway, and groups C and D having several genetic alternations
not specific to a single pathway. The gene for follistatin-like protein 5, FSTL5,
is overexpressed in nonSHH/nonWNT MBs poorly characterized. High-
expression of FSTL5 is significantly associated with reduced event-free and
overall survival in non-WNT/non-SHHMBs. The major aim of this project is
to study the FSTL5 expression level in pediatric MBs with metastasis at the
onset. METHOD: We investigated the protein expression of biomarkers in-
volved in metastatic pathways by IHC and FSTL5 expression level by
RT-PCR in 26 metastatic MBs samples and correlated these data with the out-
comes by Kaplan-Meier statistic analysis. RESULTS: 83% of Group C MBs
showed high level of FSTL5 while none of these presented down-expression.
Low-expression level of FSTL5 was find in 60% of SHH MBs and none
showed over-expression. Kaplan-Meier test revealed that, in our cohort, high-
expressionofFSTL5didnot correlatewithworseoutcomewhile lowexpression
of FSTL5 was associated with good prognosis and the co-presence of FSTL5
with other biomarkers correlated with poorer prognosis. CONCLUSION:
FSTL5 is a marker of Group C in medulloblastomas with metastasis at the
onset and the results highlighted decreased FSTL5 expression as a marker of
good prognosis. Group C MBs have characteristic molecular features that
confirm the poorest outcome also inMBs with metastasis at the onset.
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